RxDoctor Payments DataLook up a doctor →

Carl Gray, MD

Hematology & Oncology · Ogden, UTNPI 1598873382

Payments from drug & device makers

$2,516,584in general payments, 2019–2025

Across 1,358 payments — averaging $1853.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$500K
  • Novartis$439K
  • Astrazeneca UK Limited$314K
  • Regeneron$233K
  • Amgen$195K
  • AstraZeneca$170K
  • plus $666K from 54 others
$3,707in research payments, 2019–2025

Across 15 payments — averaging $247.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$3K
  • Eli Lilly$717

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC60$500,092
Novartis85$438,633
Astrazeneca UK Limited6$313,603
Regeneron70$232,732
Amgen40$195,279
AstraZeneca(2 entities)57$169,525
TG Therapeutics, Inc.72$141,612
Incyte Corporation38$113,515
Daiichi Sankyo Inc.52$89,188
Morphosys AG7$63,471
GSK43$59,195
AbbVie16$52,308
Genentech, Inc.16$30,896
Helsinn Healthcare SA7$22,843
E.r. Squibb & Sons, L.L.C.86$22,248
Boehringer Ingelheim17$14,880
Genmab A/s7$12,440
Sanofi US Services Inc.1$11,250
Tesaro, Inc.4$10,771
Bristol Myers Squibb43$8,073
Boehringer Ingelheim International GmbH8$2,470
Genentech USA, Inc.61$1,214
Pfizer80$866
Merck47$850
Astellas Pharma US Inc35$802
EMD Serono, Inc.37$666
Sanofi25$539
Seagen Inc.28$511
Johnson & Johnson(2 entities)25$462
Eisai Inc.28$460
Lilly USA, LLC21$362
Takeda Pharmaceuticals U.S.A., Inc.16$355
Pharmacyclics LLC, An Abbvie Company15$309
Sumitomo Pharma America, Inc.15$255
Amneal Pharmaceuticals LLC11$244
Array Biopharma Inc13$230
Genmab U.S., Inc.9$215
Karyopharm Therapeutics Inc.10$204
Beigene USA, Inc.7$203
Gilead(2 entities)11$198
Bayer11$184
Puma Biotechnology, Inc.10$162
Jazz Pharmaceuticals Inc.7$119
Myriad Women's Health, Inc.2$112
Regeneron Healthcare Solutions, Inc.5$108
Myovant Sciences Inc.6$107
Tersera Therapeutics LLC5$105
AVEO Pharmaceuticals, Inc.1$100
Deciphera Pharmaceuticals Inc.5$96
Sanofi-aventis U.S. LLC1$90
Pharmaessentia USA Corporation5$84
Beone Medicines USA, Inc.3$82
Dendreon Pharmaceuticals LLC4$82
Stemline Therapeutics Inc.4$73
Servier Pharmaceuticals LLC3$71
Sobi, Inc3$69
Ipsen Biopharmaceuticals, Inc4$60
Foundation Medicine, Inc.4$57
Blueprint Medicines Corporation2$57
Exelixis Inc.3$57

How this compares

$2,516,584 in reported general payments places this provider in the 90th percentile of 77 hematology & oncology providers in Utah.

See all hematology & oncology providers in Utah →

Medicare billing

Part B allowed, 2024
$12,148,950
Medicare patients
373
Services billed
512,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Ogden

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →